Abstract
The proportion of patients with ischaemic stroke treated by intravenous (i.v.) recombinant tissue plasminogen activator (rt-PA) is an indicator of quality of stroke care. The objective of the study is to evaluate the rate of i.v. thrombolysis in the North-of-France region and its evolution over time. We determined the proportion of inhabitants treated by i.v. rt-PA in 2009–2010 (period A; 8 stroke units, no telemedicine) and 2012 (period B; population campaigns, 12 stroke units with telemedicine in 5). We used hospital registries from the 12 stroke units, and population-based data were collected in a subpopulation of 226,827 inhabitants (5.6 % of the whole population). 1,563 inhabitants received i.v. rt-PA for stroke (period A: 835 in 24 months; period B: 728 in 12 months). Hospital and population data were similar. Annual rates of thrombolysis increased from 103 per million inhabitants [95 % confidence interval (CI) 85–125] to 181 (95 % CI 157–209; relative increase 76 %, 95 % CI 67–83 %). This rate increased in 12 districts (significantly in 6), but the increase was greater in districts where new stroke units, telemedicine, or both were implemented. In conclusion, although the proportion of patients treated was already high in period A, there was still place for improvement. Implementation of new stroke units, extension of the telemedicine network and new population campaigns are necessary to improve the rate of thrombolysis in several areas, to ensure an equal access to treatment over the whole territory. The next step is now to determine whether this high rate of i.v. rt-PA delivery at the population level translates into clinical results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Langhorne P, Williams BO, Gilchrist W, Howie K (1993) Do stroke units save lives? Lancet 342:395–398
International-Stroke-Trial-Collaborative-Group (1997) The international stroke trial (IST): a randomised trial if aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569–1581
CAST-Collaborative-Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641–1649
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333:1581–1587
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 359:1317–1329
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375:1695–1703
Vahedi K, Hofmeijer J, Jüttler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W (2007) Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6(3):215–222
Hill MD, Buchan AM (2005) Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study (CASES). CMAJ 172:1307–1312
Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J (2006) Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 37:440–446
Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369:275–282
Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR (2008) Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372:1303–1309
Leys D, Ringelstein EB, Kaste M, Hacke W (2007) The main components of stroke unit care: results of a European expert survey. Cerebrovasc Dis 23:344–352
Audebert HJ, Moulin T (2009) Telestroke: the use of telemedicine in stroke care. Preface. Cerebrovasc Dis 27(Suppl 4):V–VI
Liman TG, Winter B, Waldschmidt C, Zerbe N, Hufnagl P, Audebert HJ, Endres M (2012) Telestroke ambulances in prehospital stroke management: concept and pilot feasibility study. Stroke 43:2086–2090
Leys D, Ringelstein EB, Kaste M, Hacke W (2007) Facilities available in European hospitals treating stroke patients. Stroke 38:2985–2991
The European Stroke Organisation (ESO) executive committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507 (updated at: http://www.eso-stroke.org/pdf/ESO%420Guidelines_update_Jan_2009.pdf)
Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA (2006) Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 63:661–664
Derex L, Adeleine P, Nighoghossian N, Honnorat J, Trouillas P (2002) Factors influencing early admission in a French stroke unit. Stroke 33:153–159
Evenson KR, Foraker RE, Morris DL, Rosamond WD (2009) A comprehensive review of prehospital and in-hospital delay times in acute stroke care. Int J Stroke 4:187–199
Casolla B, Bodenant M, Girot M, Cordonnier C, Pruvo JP, Wiel E, Leys D, Goldstein P (2013) Intra-hospital delays in stroke patients treated with rt-PA: impact of preadmission notification. J Neurol 260:635–639
Lichtman JH, Watanabe E, Allen NB, Jones SB, Dostal J, Goldstein LB (2009) Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001–2004. Stroke 40:3845–3850
Leys D, Cordonnier C, Debette S, Hacke W, Ringelstein EB, Giroud M, Mas JL, Kaste M (2009) Facilities available in French hospitals treating acute stroke patients: comparison with 24 other European countries. J Neurol 256:867–873
Bodenant M, Leys D, Debette S, Cordonnier C, Dumont F, Henon H, Girot M, Lucas C, Devos D, Defebvre L, Deplanque D, Leclerc X, Bordet R (2010) Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 30:148–156
Cordonnier C, Girot M, Dorp E, Rimetz P, Bouillaguet S, Henon H, Lucas C, Godefroy O, Leys D (2000) Stroke units from scientific evidence to practice: the experience of the Lille stroke unit. Cerebrovasc Dis 10(Suppl 4):17–20
Mihout M, Cordonnier C, Girard-Buttaz I, Leys D (2012) Thrombolysis for ischaemic stroke: impact of the extension of the time-window in daily practice. J Neurol Neurosurg Psychiatry 83:227–228
Adeoye O, Hornung R, Khatri P, Kleindorfer D (2011) Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 42:1952–1955
Fang MC, Cutler DM, Rosen AB (2010) Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med 5:406–409
Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, Shinohara Y, Yamaguchi T (2010) Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41:1984–1989
Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D (2010) Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry 82:14–19
Vanacker P, Thijs V, Peeters A, Bruneel B, Laloux P, Druwe P, De Deyn P, Ahmed N, Wahlgren N, Vanhooren G (2012) The Belgian experience with intravenous thrombolysis for acute ischemic stroke. Acta Neurol Belg 110:157–162
Leyden JM, Chong WK, Kleinig T, Lee A, Field JB, Jannes J (2011) A population-based study of thrombolysis for acute stroke in South Australia. Med J Aust 194:111–115
Kim YS, Park SS, Bae HJ, Cho AH, Cho YJ, Han MK, Heo JH, Kang K, Kim DE, Kim HY, Kim GM, Kwon SU, Kwon HM, Lee BC, Lee KB, Lee SH, Lee SH, Lee YS, Nam HS, Oh MS, Park JM, Rha JH, Yu KH, Yoon BW (2011) Stroke awareness decreases prehospital delay after acute ischemic stroke in Korea. BMC Neurol 11:2
Kobayashi A, Czlonkowska A, Ahmed N, Romanowicz S, Glonek M, Nyka WM, Opala G, Wahlgren N (2010) Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the safe implementation of thrombolysis in stroke (SITS) registry. Acta Neurol Scand 122:229–236
Gladstone DJ, Rodan LH, Sahlas DJ, Lee L, Murray BJ, Ween JE, Perry JR, Chenkin J, Morrison LJ, Beck S, Black SE (2009) A citywide prehospital protocol increases access to stroke thrombolysis in Toronto. Stroke 40:3841–3844
International-stroke-Trial-Collaborative-Group (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke [the third international stroke trial (IST-3)]: a randomised controlled trial. Lancet 379(9834):2352–2363
Acknowledgments
University Lille Nord de France (EA 1046) and Adrinord.
Conflicts of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The first three authors N. Dequatre-Ponchelle, H. Touzani and A. Banh had an equal contribution.
The last three authors J.P. Pruvo, P. Goldstein and D. Leys had an equal contribution
Rights and permissions
About this article
Cite this article
Dequatre-Ponchelle, N., Touzani, H., Banh, A. et al. Rate of intravenous thrombolysis for acute ischaemic stroke in the North-of-France region and evolution over time. J Neurol 261, 1320–1328 (2014). https://doi.org/10.1007/s00415-014-7344-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-014-7344-5